1. Studies on Values of Digital Health
- Author
-
Lee, Jeannie K., Erstad, Brian L., McBride, Ali, Edwards, Christopher J., Choi, Briana, Lee, Jeannie K., Erstad, Brian L., McBride, Ali, Edwards, Christopher J., and Choi, Briana
- Abstract
Background: The landscape of digital health technologies (DHTs) has evolved significantly, encompassing diverse technologies and platforms. Among these, digital therapeutics (DTx) are software interventions designed to manage diseases and health conditions. Chronic insomnia, characterized by difficulty initiating or maintaining sleep with associated daytime symptoms, affects approximately 8% of adults in the United States (US) and imposes significant burdens on individuals and healthcare systems. Cognitive behavioral therapy for insomnia (CBT-I) is recommended as a first-line treatment, but its utilization is limited due to a shortage of certified providers. Somryst (Nox Health, Alpharetta, GA, US), a US Food and Drug Administration (FDA)-approved DTx, offers an alternative for delivering CBT-I. Objectives: This study aims to evaluate the current landscape of value frameworks for DHTs and DTx through a narrative review, as well as assess the economic impact of Somryst for chronic insomnia management. Methods: A literature search was conducted from September 2023 to January 2024 across multiple databases and websites, focusing on value frameworks for DHTs and DTx. A narrative approach was used to review and summarize findings from selected articles, assessing key elements of identified value frameworks based on previously identified value domains. Additionally, two budget impact analyses were performed over 1-year (primary analysis) and 3-year (secondary analysis) time horizons for (1) the total US population (net budget impact), and (2) a 1-million-member health plan (net budget impact, per-member-per-year (PMPY), per-member-per-month (PMPM)) using Excel. Costs and clinical outcomes associated with Somryst, CBT-I, CBT-I+self-help, and eszopiclone were derived from published literature, Merative Micromedex Red Book, and the Physician Fee Schedule. A scenario analysis using upper limits of probabilities of no-remission was conducted. A decision-tree model was specifie
- Published
- 2024